Shares of US-based biotechnology company Sellas Life Sciences extended their spectacular rally on Wednesday, November 18, rising another 5% after soaring nearly 156% in the previous session.
The stock has come under investors' radar following a major breakthrough in a late-stage clinical trial of its experimental cancer vaccine, which demonstrated a significant improvement in survival outcomes among patients with an aggressive form of blood cancer.
The sharp rally came after the company announced positive results from its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine designed to treat acute myeloid leukaemia (AML).
The results marked a significant milestone for the company, with the trial meeting its primary endpoint of overall survival. Sellas said the treatment reduced the risk of death by 41% compared with the best available treatment, with a hazard ratio of 0.59 and a statistically significant p-value of 0.035, as per the company's press release.
The company said that the 126-patient study showed that patients receiving GPS achieved median overall survival of 24 months, compared with 14.7 months among those receiving the best available treatment.
Acute Myeloid Leukemia (AML) is an aggressive cancer affecting the blood and bone marrow. According to the company, the vaccine works by training the body's immune system to identify and attack residual leukaemia cells carrying the WT1 protein.
The treatment was also generally well tolerated, with no new safety concerns identified and most treatment-related adverse events being mild to moderate.
The positive clinical findings have raised expectations around the vaccine's commercial potential and the company's regulatory roadmap. Sellas said it plans to meet with the US Food and Drug Administration (FDA) to discuss an accelerated filing strategy while advancing preparations for a Biologics License Application (BLA), targeting submission in the first half of 2027.
The results have also drawn positive attention from analysts. Alliance Global Partners analyst James Molloy described the findings as clinically meaningful and indicated that the treatment could potentially receive expedited approval in 2027, as per the media reports.
However, investors also have a potential dilution risk to consider. On November 17, Sellas announced an underwritten public offering of $150 million in common stock, with an additional 30-day option for underwriters to purchase shares worth up to $22.5 million. J.P. Morgan and TD Cowen are acting as joint book-running managers.
The proposed offering is intended to provide additional capital to the company, but the issuance of fresh shares could dilute existing shareholders.
Despite the fundraising announcement, investor enthusiasm surrounding the Phase 3 trial results has remained the dominant driver of the stock's recent rally. The next key triggers for investors will be the company's discussions with the FDA, further clinical data disclosures, and progress towards its targeted 2027 regulatory filing.
Disclaimer: We advise investors to check with certified experts before making any investment decisions.
Ksheera Sagar has been working as a Market Research Analyst at LiveMint for the past four years, covering stocks, commodities, and broader financial markets. In this role, he closely tracks daily market movements, corporate earnings, sector trends, and macroeconomic developments. <br><br> He has over a decade of experience in the financial services industry and has previously worked with multiple organisations, including global investment bank J.P. Morgan, bringing strong research experience into the newsroom. <br><br> During his career, he has gained extensive exposure to equity research, market analysis, and financial data interpretation, strengthening his expertise across asset classes and market cycles. <br><br> He is known for his data-driven analysis and crisp, listicle-style market stories that break down complex financial developments across key markets for a wide audience. His strong research skills enable him to write detailed and insightful stories on stocks and sectors, focusing on the underlying factors driving market movements. <br><br> His work combines quantitative insights with clear storytelling, presenting financial developments in a clear and structured manner. Moreover, he enjoys writing multibagger and listicle-style copies. Outside of work, Ksheera enjoys playing the piano and exploring new places. He has a keen interest in travel, music, and continuously learning about global markets and economic trends.
Catch all the Business News , Market News , Breaking News Events, JIO IPO Listing Today LIVE and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.